Burden of disease in myasthenia gravis: taking the patient's perspective.
Burden of disease
Myasthenia gravis
Quality of life
Real-world setting
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
29
06
2021
accepted:
02
11
2021
revised:
10
10
2021
pubmed:
21
11
2021
medline:
24
5
2022
entrez:
20
11
2021
Statut:
ppublish
Résumé
Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but also psychological and social well-being are limited. We aim to describe the burden of disease in MG including sociodemographic, economical, psychosocial as well as clinical aspects, to compare health-related quality of life (HRQoL) of patients with MG to the general population (genP) and to explore risk factors for a lower HRQoL. This case-control study was conducted with MG patients of the German Myasthenia Association. A questionnaire-based survey included sociodemographic and clinical data as well as standardized questionnaires, e.g. the Short Form Health (SF-36). HRQoL was compared to genP in a matched-pairs analysis. Participants of the German Health Interview and Examination Survey for Adults (DEGS1) served as control group. In our study, 1660 MG patients participated and were compared to 2556 controls from the genP. Patients with MG showed lower levels of physical functioning (SF-36 mean 56.0, SD 30.3) compared to the genP (mean 81.8, SD 22.1, adjusted difference: 25, 95% CI 22-29) and lower mental health sub-score (SF-36 mean 67.3, SD 19.8, vs. 74.1, SD 16.7, adjusted difference: 5, 95% CI 2-8). Female gender, higher age, low income, partnership status, lower activities of daily life, symptoms of depression, anxiety and fatigue and self-perceived low social support were associated with a lower HRQoL in MG patients. HRQoL is lower in patients with MG compared to genP. The burden of MG on patients includes economic and social aspects as well as their emotional well-being. New therapies must achieve improvements for patients in these areas. Clinicaltrials.gov, NCT03979521, submitted: June 7, 2019, first patient enrolled: May 1, 2019, https://clinicaltrials.gov/ct2/show/NCT03979521.
Sections du résumé
BACKGROUND
BACKGROUND
Myasthenia gravis (MG) leads to exertion-dependent muscle weakness, but also psychological and social well-being are limited. We aim to describe the burden of disease in MG including sociodemographic, economical, psychosocial as well as clinical aspects, to compare health-related quality of life (HRQoL) of patients with MG to the general population (genP) and to explore risk factors for a lower HRQoL.
METHODS
METHODS
This case-control study was conducted with MG patients of the German Myasthenia Association. A questionnaire-based survey included sociodemographic and clinical data as well as standardized questionnaires, e.g. the Short Form Health (SF-36). HRQoL was compared to genP in a matched-pairs analysis. Participants of the German Health Interview and Examination Survey for Adults (DEGS1) served as control group.
RESULTS
RESULTS
In our study, 1660 MG patients participated and were compared to 2556 controls from the genP. Patients with MG showed lower levels of physical functioning (SF-36 mean 56.0, SD 30.3) compared to the genP (mean 81.8, SD 22.1, adjusted difference: 25, 95% CI 22-29) and lower mental health sub-score (SF-36 mean 67.3, SD 19.8, vs. 74.1, SD 16.7, adjusted difference: 5, 95% CI 2-8). Female gender, higher age, low income, partnership status, lower activities of daily life, symptoms of depression, anxiety and fatigue and self-perceived low social support were associated with a lower HRQoL in MG patients.
DISCUSSION
CONCLUSIONS
HRQoL is lower in patients with MG compared to genP. The burden of MG on patients includes economic and social aspects as well as their emotional well-being. New therapies must achieve improvements for patients in these areas.
TRIAL REGISTRATION INFORMATION
UNASSIGNED
Clinicaltrials.gov, NCT03979521, submitted: June 7, 2019, first patient enrolled: May 1, 2019, https://clinicaltrials.gov/ct2/show/NCT03979521.
Identifiants
pubmed: 34800167
doi: 10.1007/s00415-021-10891-1
pii: 10.1007/s00415-021-10891-1
pmc: PMC9120127
doi:
Banques de données
ClinicalTrials.gov
['NCT03979521']
Types de publication
Clinical Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3050-3063Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2021. The Author(s).
Références
Neurology. 2000 Jul 12;55(1):16-23
pubmed: 10891897
BMC Neurol. 2016 Nov 17;16(1):224
pubmed: 27855651
Ther Adv Neurol Disord. 2019 Mar 01;12:1756286419832242
pubmed: 30854027
Lancet Neurol. 2017 Dec;16(12):976-986
pubmed: 29066163
BMJ Open. 2017 Feb 23;7(2):e013278
pubmed: 28235967
PLoS One. 2018 Nov 8;13(11):e0206754
pubmed: 30408057
J Am Coll Health. 2007 Jul-Aug;56(1):69-74
pubmed: 17711829
Nat Rev Dis Primers. 2019 May 2;5(1):30
pubmed: 31048702
J Psychosom Res. 1993;37(2):147-53
pubmed: 8463991
Int J Neurosci. 2016;126(5):455-62
pubmed: 26000922
Muscle Nerve. 2008 Aug;38(2):957-63
pubmed: 18642357
Occup Med (Lond). 2015 Jan;65(1):86
pubmed: 25559796
J Clin Neurosci. 2015 Jul;22(7):1164-9
pubmed: 26021730
Muscle Nerve. 2001 Apr;24(4):512-6
pubmed: 11268023
Ther Adv Neurol Disord. 2018 Jan 18;11:1756285617749134
pubmed: 29403543
Muscle Nerve. 2019 Feb;59(2):218-223
pubmed: 30311960
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):631-6
pubmed: 23703479
Neurology. 1999 Apr 22;52(7):1487-9
pubmed: 10227640
J Psychosom Res. 2002 Feb;52(2):69-77
pubmed: 11832252
Brain Behav. 2016 Aug 02;6(10):e00538
pubmed: 27781147
Neurology. 2009 Jul 14;73(2):150-1
pubmed: 19597135
J Clin Neurol. 2019 Jul;15(3):376-385
pubmed: 31286711
J Neurol Neurosurg Psychiatry. 2003 Jun;74(6):710-4
pubmed: 12754336
J Clin Neuromuscul Dis. 2019 Jun;20(4):173-181
pubmed: 31135620
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013 May;56(5-6):620-30
pubmed: 23703478
Am Heart J. 2000 Jan;139(1 Pt 1):1-9
pubmed: 10618555
Scand J Caring Sci. 2009 Sep;23(3):529-38
pubmed: 19302397
Acta Neurol Scand Suppl. 2014;(198):26-31
pubmed: 24588503
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
Muscle Nerve. 2012 Aug;46(2):174-80
pubmed: 22806365
Semin Arthritis Rheum. 2014 Oct;44(2):123-30
pubmed: 24973898
Neurol Sci. 2010 Feb;31(1):41-5
pubmed: 19816655
Neurol Sci. 2001 Oct;22(5):363-9
pubmed: 11917973
Muscle Nerve. 2014 Oct;50(4):493-500
pubmed: 24536040
Health Qual Life Outcomes. 2010 Nov 11;8:129
pubmed: 21070628
Muscle Nerve. 2002 Mar;25(3):466-7
pubmed: 11870729
Muscle Nerve. 2019 Dec;60(6):707-715
pubmed: 31487038
Muscle Nerve. 2015 Sep;52(3):371-9
pubmed: 25557017
Neurol Sci. 2012 Dec;33(6):1375-81
pubmed: 22875151
Health Qual Life Outcomes. 2015 Aug 01;13:115
pubmed: 26232146
Neurol Sci. 2021 Jan;42(1):167-173
pubmed: 32592102